SS-31 dose range
The amounts people commonly use, from the low end to the high end, with syringe units, schedule and half-life. The 11 published studies are one click away.
Human trials Mitochondrial Also called Elamipretide
Common use ranges
From user guides and clinic write-ups. No drug label exists, and no study has tested these amounts in people. Sources agree on once a day and on 5 to 10 mg as the common range, but there is no trial data at those doses.
- Half-life
- Not measured in any published study
- How it is taken
- Shot under the skin (subcutaneous)
- How long people use it
- Community use runs about 4 to 12 weeks. A common pattern is 12 weeks on, 4 weeks off. Another guide says 4 to 8 weeks. The approved drug is taken every day with no break.
- Mixing used for the units
- 50 mg vial + 1 mL water. 1 unit on a U-100 insulin syringe = 500 mcg.
Pick your vial size and how much water you add. The units below change to match.
50 mg vial + 1 mL water: 1 unit = 500 mcg
| Tier | Each dose | Syringe units50 mg vial + 1 mL water | How often | Schedule | Vial lastsat this tier |
|---|---|---|---|---|---|
| Starting [1] | 5 mg | 10 units 0.10 mL | once a day | 5 mg once a day. This is the low end of the common community range. One guide lists an even lower 0.5 to 5 mg a day. | 10 days |
| Typical [2] | 10 mg | 20 units 0.20 mL | once a day | 10 mg once a day, the top of the 5 to 10 mg community range. | 5 days |
| Higher [3] | 20 mg | 40 units 0.40 mL | once a day | Some cycling protocols go up to 10 to 20 mg once a day. | 2 days |
| Approved drug dose (Barth syndrome) [4] | 40 mg | 80 units 0.80 mL | once a day | 40 mg once a day under the skin, every day, for patients 30 kg and up. 20 mg a day with severe kidney problems. This is the prescription label for one rare disease, not a common-use dose. | 1 day |
Good to know
- Elamipretide is FDA approved as Forzinity only for Barth syndrome. Every other use is off label.
- Community doses are about one eighth to one quarter of the 40 mg label dose. One source says this is driven by cost, not by evidence.
- All sources agree on once a day, under the skin.
- Vials are sold as 10 mg and 50 mg powder.
Sources for these amounts
- Starting: Outliyr SS-31 report · Peptide Protocol Wiki, SS-31 dosing · The Dose Guide, SS-31
- Typical: Outliyr SS-31 report · Peptide Protocol Wiki, SS-31 dosing
- Higher: Outliyr SS-31 report
- Approved drug dose (Barth syndrome): Outliyr SS-31 report (summarizes the Forzinity label) · Peptide Protocol Wiki, SS-31 dosing (trial doses)
How long people use it: Outliyr SS-31 report · The Dose Guide, SS-31 · Peptide Protocol Wiki, SS-31 dosing
Half-life: Forzinity (elamipretide) FDA label on DailyMed, section 12.3
Take the SS-31 chart with you
Get a one-page printable chart for SS-31, with the syringe units for each vial and water mix. We can also email you when a new SS-31 study is published.
This page shows what labels, clinics and users report, and what studies gave. It is not medical advice and not a recommendation for anyone. Many of these compounds are not approved for human use. Check your own medicines and lab work with a licensed clinician before using anything.
See the science: 11 published studies
Amounts given to people in studies
How it was given: Under the skin (SC). Early studies used IV.
Trials ran from 4 weeks to more than 3 years.
Amounts given to animals in studies
Every study used for this page
Proof grade: Human trials. Tested in randomized human trials. Amounts are quoted as each study reported them. Where the abstract does not state an amount, the row says so.
| Study | Who was studied | Amount given, as reported | Route | How often | How long | What the authors reported |
|---|---|---|---|---|---|---|
| PMID 320680022020 | Human, HFrEF (n=71) | 4 mg or 40 mg (LOW human SC) | SC | once daily | 28 consecutive days | No change in LV end-systolic volume vs placebo; well tolerated |
| PMID 295002922018 | Human, primary mitochondrial myopathy (n=36) | 0.01, 0.1, 0.25 mg/kg/h for 2 hours, dose-escalating (LOWEST per-kg human) | IV infusion | once daily | 5 days of treatment | Highest dose 64.5 m vs 20.4 m placebo on 6MWT (p=0.053), dose-dependent trend |
| PMID 320966132020 | Human, primary mitochondrial myopathy, crossover (n=30) | 40 mg/day | SC | daily | 4 weeks (then 4-wk washout, crossover) | 6MWT +19.8 m (p=0.0833), less fatigue on symptom scales |
| PMID 372684352023 | Human, PMM, phase 3 (n=218; 109 vs 109) | 40 mg/d | SC | daily | 24 weeks | Missed primary endpoints (6MWT, PMMSA fatigue) |
| PMID 386021812024 | Human, Barth syndrome open-label ext (n=10 entered, 8 reached wk 168) | 40 mg SC daily | SC | daily | 168 weeks (after 28-wk RCT) | Sustained 6MWT improvement (+96.1 m cumulative at wk 168) |
| PMID 396058742025 | Human, dry AMD with geographic atrophy (n=176; 117 vs 59) | 40 mg daily | SC | daily | 48 weeks plus 4 wk follow-up | Primary endpoints missed, slowed ellipsoid-zone loss |
| PMID 362501632022 | Mouse, aged and diet models (n not recorded; wt not stated, ~0.025 kg assumed) | 3 mg/kg | SC | 5 days per week | 10 months (18 to 28 months of age) | Healthier aging phenotypes (PMC full text) |
| PMID 317479052019 | Mouse C57BL/6 male, 21-23 g (n not recorded) | 5 mg/kg | IP | once 30 min pre-surgery, then daily x3 | 3 days | Less LPS-induced mitochondrial and memory impairment. Authors say 5 mg/kg is the most effective repeated dose in mouse models |
| PMID 297140402018 | Pig, metabolic syndrome (n=6 per group; wt not stated) | 0.1 mg/kg | SC | daily, 5 days/week | 4 weeks | Preserved renal microvasculature |
| PMID 242883962014 | Rabbit and guinea pig, ischemia/reperfusion (wt not recorded) | 0.05 mg/kg/hr (as "Bendavia") | IV infusion | continuous | 1 to 3 hours of reperfusion | Cut infarct size about 50% |
| PMID 310057512019 | Mouse, irradiation (n and wt not in abstract) | 6 mg/kg | route not in abstract | not in abstract | not in abstract | Higher survival after lethal radiation |
How to read the study numbers
- One study, one group. Each figure is what one team chose for its own participants or animals.
- Route matters. An amount given into a vein (IV) is not the same as the same amount under the skin, in the nose or by mouth.
- Animals are not small people. An animal amount is shown as the study gave it. It is not a human amount.
- Short studies. Many studies ran days or weeks. They do not show what happens over longer use.
Common questions
What amounts of SS-31 were used in human studies?
In the studies listed here, people were given from 4 mg daily up to 40 mg daily. The amount used most often was 40 mg daily. These are what study teams chose for their participants under supervision.
Where do these SS-31 numbers come from?
From 11 published studies, each linked to its PubMed or ClinicalTrials.gov record. Every figure was checked against the study abstract or its open full text. Proof grade: Human trials.
How long does SS-31 stay in the body?
No published study has measured the half-life of SS-31, so nobody knows exactly how long one dose stays in the blood.
Is this a recommendation for how much SS-31 to use?
No. This page shows the amounts reported by drug labels, clinics and users, next to what researchers gave in studies. It is not medical advice and not a recommendation for anyone. Talk to a licensed clinician before using any of it.